WallStreetZenWallStreetZen

NASDAQ: IBRX
Immunitybio Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

IBRX past revenue growth

How has IBRX's revenue growth performed historically?
Company
159.17%
Industry
145.63%
Market
17.92%
IBRX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
IBRX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
IBRX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

IBRX earnings and revenue history

Current Revenue
$622.0k
Current Earnings
-$583.2M
Current Profit Margin
-93,761.4%

IBRX Return on Equity

Current Company
N/A
Current Industry
-63.5%
Current Market
188%

Be the first to know when IBRX announces earnings.

IBRX Return on Assets

Current Company
-148.4%
Current Industry
2.9%
IBRX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

IBRX Return on Capital Employed

Current Company
-101.76%
Current Industry
19.5%
IBRX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

IBRX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
IBRX$622.00k-$429.41M-$583.20M+67.62%N/A
IONS$787.65M-$230.01M-$366.29M+5.60%N/A
APLS$396.59M-$495.21M-$528.63M+83.50%N/A
EXEL$1.85B$312.76M$205.05M+16.63%-21.67%
RVMD$11.58M-$430.28M-$436.37M-10.50%N/A
View Top Biotech Stocks

IBRX earnings dates

Next earnings date
Jun 11, 2024

Immunitybio Earnings & Revenue FAQ

What were IBRX's earnings last quarter?

On Invalid Date, Immunitybio (NASDAQ: IBRX) reported Q4 2023 earnings per share (EPS) of -$0.38, up 40.74% year over year. Total Immunitybio earnings for the quarter were -$233.39 million. In the same quarter last year, Immunitybio's earnings per share (EPS) was -$0.27.

If you're new to stock investing, here's how to buy Immunitybio stock.

What was IBRX's earnings growth in the past year?

As of Q2 2024, Immunitybio's earnings has grown year over year. Immunitybio's earnings in the past year totalled -$583.20 million.

What is IBRX's earnings date?

Immunitybio's earnings date is Invalid Date. Add IBRX to your watchlist to be reminded of IBRX's next earnings announcement.

What was IBRX's revenue last quarter?

On Invalid Date, Immunitybio (NASDAQ: IBRX) reported Q4 2023 revenue of $139.00 thousand up 90.41% year over year. In the same quarter last year, Immunitybio's revenue was $73.00 thousand.

What was IBRX's revenue growth in the past year?

As of Q2 2024, Immunitybio's revenue has grown 159.17% year over year. This is 13.53 percentage points higher than the US Biotechnology industry revenue growth rate of 145.63%. Immunitybio's revenue in the past year totalled $622.00 thousand.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.